Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Spotlight on Clinical Response

  • Spotlight on Clinical Response
    BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
    Udai Banerji, Annette Affolter, Ian Judson, Richard Marais and Paul Workman
    Mol Cancer Ther April 1 2008 7 (4) 737-739; DOI:10.1158/1535-7163.MCT-08-0145

Review

  • Review
    Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics
    Annamaria Hadnagy, Raymond Beaulieu and Danuta Balicki
    Mol Cancer Ther April 1 2008 7 (4) 740-748; DOI:10.1158/1535-7163.MCT-07-2284

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels
    Catherine A. Tucker, Anita I. Kapanen, Ghania Chikh, Brad G. Hoffman, Alastair H. Kyle, Ian M. Wilson, Dana Masin, Randy D. Gascoyne, Marcel Bally and Richard J. Klasa
    Mol Cancer Ther April 1 2008 7 (4) 749-758; DOI:10.1158/1535-7163.MCT-07-0302

  • Research Articles: Therapeutics, Targets, and Development
    MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
    Marielle Fournel, Claire Bonfils, Yu Hou, Pu Theresa Yan, Marie-Claude Trachy-Bourget, Ann Kalita, Jianhong Liu, Ai-Hua Lu, Nancy Z. Zhou, Marie-France Robert, Jeffrey Gillespie, James J. Wang, Hélène Ste-Croix, Jubrail Rahil, Sylvain Lefebvre, Oscar Moradei, Daniel Delorme, A. Robert MacLeod, Jeffrey M. Besterman and Zuomei Li
    Mol Cancer Ther April 1 2008 7 (4) 759-768; DOI:10.1158/1535-7163.MCT-07-2026

  • Research Articles: Therapeutics, Targets, and Development
    Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia
    C. James Chou, Michelle E. Farkas, Sherry M. Tsai, David Alvarez, Peter B. Dervan and Joel M. Gottesfeld
    Mol Cancer Ther April 1 2008 7 (4) 769-778; DOI:10.1158/1535-7163.MCT-08-0130

  • Research Articles: Therapeutics, Targets, and Development
    Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models
    Yasushi Sasaki, Hideaki Negishi, Masashi Idogawa, Hiromu Suzuki, Hiroaki Mita, Minoru Toyota, Yasuhisa Shinomura, Kohzoh Imai and Takashi Tokino
    Mol Cancer Ther April 1 2008 7 (4) 779-787; DOI:10.1158/1535-7163.MCT-07-0395

  • Research Articles: Therapeutics, Targets, and Development
    Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma
    Nathan R. Miselis, Zhijin J. Wu, Nico Van Rooijen and Agnes B. Kane
    Mol Cancer Ther April 1 2008 7 (4) 788-799; DOI:10.1158/1535-7163.MCT-07-0579

  • Research Articles: Therapeutics, Targets, and Development
    Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor
    Shu-Chuan Weng, Yoko Kashida, Samuel K. Kulp, Dasheng Wang, Robert W. Brueggemeier, Charles L. Shapiro and Ching-Shih Chen
    Mol Cancer Ther April 1 2008 7 (4) 800-808; DOI:10.1158/1535-7163.MCT-07-0434

  • Research Articles: Therapeutics, Targets, and Development
    2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition
    Diansheng Zhong, Xiuju Liu, Katherine Schafer-Hales, Adam I. Marcus, Fadlo R. Khuri, Shi-Yong Sun and Wei Zhou
    Mol Cancer Ther April 1 2008 7 (4) 809-817; DOI:10.1158/1535-7163.MCT-07-0559

  • Research Articles: Therapeutics, Targets, and Development
    Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy
    Cathy Zhang, Karen Lundgren, Zhengming Yan, Maria E. Arango, Sharon Price, Andrea Huber, Joseph Higgins, Gabriel Troche, Judith Skaptason, Tatiana Koudriakova, Jim Nonomiya, Michelle Yang, Patrick O'Connor, Steve Bender, Gerrit Los, Cristina Lewis and Bart Jessen
    Mol Cancer Ther April 1 2008 7 (4) 818-828; DOI:10.1158/1535-7163.MCT-07-0440

  • Research Articles: Therapeutics, Targets, and Development
    LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
    Davide Melisi, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese and Paul J. Chiao
    Mol Cancer Ther April 1 2008 7 (4) 829-840; DOI:10.1158/1535-7163.MCT-07-0337

  • Research Articles: Therapeutics, Targets, and Development
    Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma
    Jack S. Chen, Linda J. Zhou, Michal Entin-Meer, Xiaodong Yang, Mila Donker, Zachary A. Knight, William Weiss, Kevan M. Shokat, Daphne Haas-Kogan and David Stokoe
    Mol Cancer Ther April 1 2008 7 (4) 841-850; DOI:10.1158/1535-7163.MCT-07-0393

  • Research Articles: Therapeutics, Targets, and Development
    Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature
    Lin Cao, Pan Du, Shu-Han Jiang, Guang-Hui Jin, Qi-Lai Huang and Zi-Chun Hua
    Mol Cancer Ther April 1 2008 7 (4) 851-861; DOI:10.1158/1535-7163.MCT-07-0533

  • Research Articles: Therapeutics, Targets, and Development
    Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
    Jorge L. Martínez-Torrecuadrada, Lawrence H. Cheung, Paula López-Serra, Rodrigo Barderas, Marta Cañamero, Sergio Ferreiro, Michael G. Rosenblum and J. Ignacio Casal
    Mol Cancer Ther April 1 2008 7 (4) 862-873; DOI:10.1158/1535-7163.MCT-07-0394

  • Research Articles: Therapeutics, Targets, and Development
    The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
    Nadia Godin-Heymann, Lindsey Ulkus, Brian W. Brannigan, Ultan McDermott, Jennifer Lamb, Shyamala Maheswaran, Jeffrey Settleman and Daniel A. Haber
    Mol Cancer Ther April 1 2008 7 (4) 874-879; DOI:10.1158/1535-7163.MCT-07-2387

  • Research Articles: Therapeutics, Targets, and Development
    The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex–interactive agents
    Daekyu Sun, Wei-Jun Liu, Kexiao Guo, Jadrian J. Rusche, Scot Ebbinghaus, Vijay Gokhale and Laurence H. Hurley
    Mol Cancer Ther April 1 2008 7 (4) 880-889; DOI:10.1158/1535-7163.MCT-07-2119

  • Research Articles: Therapeutics, Targets, and Development
    Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells
    Grazia Ambrosini, Haider S. Cheema, Sharon Seelman, Allison Teed, Elliot B. Sambol, Samuel Singer and Gary K. Schwartz
    Mol Cancer Ther April 1 2008 7 (4) 890-896; DOI:10.1158/1535-7163.MCT-07-0518

  • Research Articles: Therapeutics, Targets, and Development
    Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells
    Deepika Dhawan, Antonella Borgatti Jeffreys, Rong Zheng, Jane C. Stewart and Deborah W. Knapp
    Mol Cancer Ther April 1 2008 7 (4) 897-904; DOI:10.1158/1535-7163.MCT-07-0313

  • Research Articles: Therapeutics, Targets, and Development
    UBE1L represses PML/RARα by targeting the PML domain for ISG15ylation
    Sumit J. Shah, Steven Blumen, Ian Pitha-Rowe, Sutisak Kitareewan, Sarah J. Freemantle, Qing Feng and Ethan Dmitrovsky
    Mol Cancer Ther April 1 2008 7 (4) 905-914; DOI:10.1158/1535-7163.MCT-07-0515

  • Research Articles: Therapeutics, Targets, and Development
    Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells
    Maria Serova, Aïda Ghoul, Karim A. Benhadji, Sandrine Faivre, Christophe Le Tourneau, Esteban Cvitkovic, Francois Lokiec, Janet Lord, Steven M. Ogbourne, Fabien Calvo and Eric Raymond
    Mol Cancer Ther April 1 2008 7 (4) 915-922; DOI:10.1158/1535-7163.MCT-07-2060

  • Research Articles: Therapeutics, Targets, and Development
    SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
    Xuefei Cao, Carlos Clavijo, Xu Li, H. Helen Lin, Yuan Chen, Hsiu-Ming Shih and David K. Ann
    Mol Cancer Ther April 1 2008 7 (4) 923-934; DOI:10.1158/1535-7163.MCT-07-0540

  • Research Articles: Therapeutics, Targets, and Development
    Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines
    Joel Greshock, Jie Cheng, David Rusnak, Anne Marie Martin, Richard Wooster, Tona Gilmer, Kwan Lee, Barbara L. Weber and Tal Zaks
    Mol Cancer Ther April 1 2008 7 (4) 935-943; DOI:10.1158/1535-7163.MCT-07-2072

  • Research Articles: Therapeutics, Targets, and Development
    Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
    Judith A. Gilbert, Matthew P. Goetz, Carol A. Reynolds, James N. Ingle, Karin F. Giordano, Vera J. Suman, Hilary E. Blair, Robert B. Jenkins, Wilma L. Lingle, Monica M. Reinholz, Alex A. Adjei and Matthew M. Ames
    Mol Cancer Ther April 1 2008 7 (4) 944-951; DOI:10.1158/1535-7163.MCT-07-0570

  • Research Articles: Therapeutics, Targets, and Development
    A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
    Yanan Yang, Marie Wislez, Nobukazu Fujimoto, Ludmila Prudkin, Julie G. Izzo, Futoshi Uno, Lin Ji, Amy E. Hanna, Robert R. Langley, Diane Liu, Faye M. Johnson, Ignacio Wistuba and Jonathan M. Kurie
    Mol Cancer Ther April 1 2008 7 (4) 952-960; DOI:10.1158/1535-7163.MCT-07-2045

  • Research Articles: Therapeutics, Targets, and Development
    Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism
    Minsub Shim and Thomas E. Eling
    Mol Cancer Ther April 1 2008 7 (4) 961-971; DOI:10.1158/1535-7163.MCT-07-0470

  • Research Articles: Therapeutics, Targets, and Development
    Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A. Lubet, Eva Szabo, Konstantin Christov, Ann M. Bode, Marna E. Ericson, Vernon E. Steele, M. Margaret Juliana and Clinton J. Grubbs
    Mol Cancer Ther April 1 2008 7 (4) 972-979; DOI:10.1158/1535-7163.MCT-07-2141

  • Research Articles: Therapeutics, Targets, and Development
    WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells
    Andrew R. Cuddihy, Farid Jalali, Carla Coackley and Robert G. Bristow
    Mol Cancer Ther April 1 2008 7 (4) 980-992; DOI:10.1158/1535-7163.MCT-07-0471

  • Research Articles: Therapeutics, Targets, and Development
    Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
    Stéphane Supiot, Richard P. Hill and Robert G. Bristow
    Mol Cancer Ther April 1 2008 7 (4) 993-999; DOI:10.1158/1535-7163.MCT-07-0442

Correction

  • Correction
    Article on TRPV6 in Breast Cancer
    Mol Cancer Ther April 1 2008 7 (4) 1000-1000; DOI:10.1158/1535-7163.MCT-7-4-COR

Back to top
PreviousNext
Molecular Cancer Therapeutics: 7 (4)
April 2008
Volume 7, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma

Jump to

  • Spotlight on Clinical Response
  • Review
  • Research Articles: Therapeutics, Targets, and Development
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement